Topelia will initially focus on the development of its TPL101 Antiviral Triple Therapy for coronavirus infection, in particular for COVID-19.

Given the mechanism by which TPL101 exerts its antiviral effect, Topelia plans to target other coronaviruses including Avian influenza as well as Flavivirdae infections such as Dengue, Zika and Yellow Fever.